Abstract:Inflammatory bowel disease (IBD) is a chronic illness characterized by relapsing inflammation of the intestines. The disorder is stratified according to the severity and is marked by its two main phenotypical representations: Ulcerative colitis and Crohn's disease. Pathogenesis of the disease is ambiguous and is expected to have interactivity between genetic disposition, environmental factors such as bacterial agents, and dysregulated immune response. Treatment for IBD aims to reduce symptom extent and severity and halt disease progression. The mainstay drugs have been 5-aminosalicylates (5-ASAs), corticosteroids, and immunosuppressive agents. Parenteral, oral and rectal routes are the conventional methods of drug delivery, and among all, oral administration is most widely adopted. However, problems of systematic drug reactions and low specificity in delivering drugs to the inflamed sites have emerged with these regular routes of delivery. Novel drug delivery systems have been introduced to overcome several therapeutic obstacles and for localized drug delivery to target tissues. Enteric-coated microneedle pills, various nano-drug delivery techniques, prodrug systems, lipid-based vesicular systems, hybrid drug delivery systems, and biologic drug delivery systems constitute some of these novel methods. Microneedles are painless, they dislodge their content at the affected site, and their release can be prolonged. Recombinant bacteria such as genetically engineered and eukaryotic cells, including GM immune cells and red blood cells as nanoparticle carriers, can be plausible delivery methods when evaluating biologic systems. Nano-particle drug delivery systems consisting of various techniques are also employed as nanoparticles can penetrate through inflamed regions and adhere to the thick mucus of the diseased site. Prodrug systems such as 5-ASAs formulations or their derivatives are effective in reducing colonic damage. Liposomes can be modified with both hydrophilic and lipophilic particles and act as lipid-based vesicular systems, while hybrid drug delivery systems containing an internal nanoparticle section for loading drugs are potential routes too. Leukosomes are also considered as possible carrier systems, and results from mouse models have revealed that they control anti- and pro-inflammatory molecules.

A Survey of Drug Delivery System for Inflammatory Bowel Disease

Site-specific Targeted Drug Delivery Systems for the Treatment of Inflammatory Bowel Disease.

Novel drug delivery systems for inflammatory bowel disease.

Harnessing polymer-derived drug delivery systems for combating inflammatory bowel disease

Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease

Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: Opportunities and emerging strategies

Medicinal plant-based drug delivery system for inflammatory bowel disease

Targeting strategies of oral nano-delivery systems for treating inflammatory bowel disease

Design strategies, advances and future perspectives of colon-targeted delivery systems for the treatment of inflammatory bowel disease

Advances in Carotenoid Based Delivery Systems for Alleviating Inflammatory Bowel Disease

Advances in Macrophage-Targeting Nanoparticles for the Diagnosis and Treatment of Inflammatory Bowel Disease.

The Application of Natural Products-Delivering Micro/nano Systems in the Treatment of Inflammatory Bowel Disease

Nanoparticles for oral delivery: targeted therapy for inflammatory bowel disease

Advancements in hydrogel-based drug delivery systems for inflammatory bowel disease: a review

Nanoparticle-Based Drug Delivery Systems for Inflammatory Bowel Disease Treatment

Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives

Advancements in hydrogel-based drug delivery systems for the treatment of inflammatory bowel disease: a review

Stimulus-responsive drug delivery nanoplatforms for inflammatory bowel disease therapy

Unleashing the Potential of Oral Deliverable Nanomedicine in the Treatment of Inflammatory Bowel Disease

Recent Advances in Bacteria‐based Platforms for Inflammatory Bowel Diseases Treatment

Oral Administration of Inflammatory Microenvironment-Responsive Carrier-Free Infliximab Nanocomplex for the Targeted Treatment of Inflammatory Bowel Disease